WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 14, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that three posters highlighting the Company’s expertise in ADCs will be presented at the upcoming
Significant Operational and Financial Progress in 2017 with a Robust Set of Data and Events Expected in 2018 Mirvetuximab Soravtansine Phase 3 FORWARD I Trial to Complete Enrollment by Mid-Year; FORWARD II Combination Data to be Presented Throughout 2018 Novel ADC Pipeline Continues to Advance with
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 6, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 26, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 24, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Stuart A. Arbuckle to its Board of Directors. Mr.
Second ADC Using ImmunoGen’s Novel DNA-Alkylating Payloads to Enter the Clinic WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 4, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the first patient has
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 2, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, will present at the upcoming 36 th Annual J.P.
CD33-Targeting IMGN779 Demonstrates Favorable Safety Profile and Anti-Leukemia Activity in Ongoing Phase 1 Trial; Dose Escalation Continues with Two Dosing Schedules Preclinical Data Presentations on IMGN779 in Combination and CD123-Targeting IMGN632 Highlight Breadth of ImmunoGen Hematology
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: Jefferies 2017
Collaboration with Jazz Pharmaceuticals Accelerates Development of Early-Stage ADC Assets and Strengthens Financial Position $100+ Million Follow-on Financing Provides Two-year Operating Runway Presentations Accepted for ASH Annual Meeting Highlight Potential of Novel IGN Portfolio IMGN632